Laddar...
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP‐1RA, has recently been approved for clinical use, based on the results of the randomized, Phase 3a Peptide InnOvatioN for Early d...
Sparad:
| I publikationen: | Diabetes Obes Metab |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Blackwell Publishing Ltd
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384149/ https://ncbi.nlm.nih.gov/pubmed/32267058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14054 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|